A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores

J Clin Endocrinol Metab. 2008 Oct;93(10):3763-8. doi: 10.1210/jc.2008-0154. Epub 2008 Jul 29.

Abstract

Context: The insulin tolerance test (ITT) is the gold standard for assessment of ACTH and GH reserve in patients with suspected hypopituitarism. It is labor intensive and costly.

Objective: The objective of the study was to determine whether use of the overnight metyrapone test (OMT) and plasma IGF-I sd scores (SDS) could provide a cost-effective alternative to the ITT.

Design: This was a retrospective chart review.

Setting: The study was conducted at a teaching hospital.

Participants and intervention: Charts from 100 patients with organic pituitary disorders were reviewed. All underwent the OMT unless 0900 h plasma cortisol was less than 80 or greater than 450 nmol/liter when ACTH deficiency or ACTH sufficiency, respectively, was diagnosed. Patients were considered GH deficient if the age-related IGF-I SDS was less than -3 or if they had three or more other pituitary hormone deficiencies. Patients were considered GH sufficient if age-related IGF-I SDS was greater than the 95th centile established from patients with known GH deficiency. Thirty-three underwent an ITT.

Main outcome measures: The proportion of patients in whom ACTH and GH reserve could be assessed using OMT/IGF-I SDS was measured. The concordance with results was obtained from ITT.

Results: Fifty-five patients were ACTH sufficient and 45 were ACTH deficient. Twenty-one were GH sufficient and 33 were GH deficient based on IGF-I SDS and other pituitary hormone deficiencies, whereas 46 could not be classified. There was near-uniform concordance between OMT/IGF-I SDS and ITT. Initial investigation using OMT/IGF-I SDS resulted in a significant cost saving.

Conclusions: ACTH and GH reserve can be accurately and cost-effectively investigated using OMT/IGF-I SDS in approximately 50% of patients with organic pituitary disorders.

Publication types

  • Comparative Study
  • Evaluation Study

MeSH terms

  • Adrenocorticotropic Hormone / metabolism*
  • Adult
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Female
  • Human Growth Hormone / metabolism*
  • Humans
  • Insulin-Like Growth Factor I / analysis
  • Insulin-Like Growth Factor I / standards*
  • Male
  • Metyrapone / administration & dosage*
  • Middle Aged
  • Pituitary Function Tests / economics*
  • Pituitary Function Tests / methods*
  • Pituitary Gland / metabolism*
  • Reference Standards
  • Research Design
  • Retrospective Studies

Substances

  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • Adrenocorticotropic Hormone
  • Metyrapone